Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21870612 | 1.00 | OPRK1 (0.47) | OPRK1EPHX2EPHX1LTA4HPIK3CD | |
| SCHEMBL25769752 | 0.90 | CA1 (0.43) | OPRK1EPHX2EPHX1PIK3CDSMN1; SMN2 | |
| SCHEMBL21322299 | 0.89 | OPRK1 (0.52) | OPRK1EPHX2EPHX1PIK3CDSMN1; SMN2 | |
| SCHEMBL4109487 | 0.86 | OPRK1 (0.44) | OPRK1EPHX2EPHX1HSD11B1SMN1; SMN2 | |
| SCHEMBL14453881 | 0.85 | OPRK1 (0.43) | OPRK1EPHX2HSD11B1SMN1; SMN2HSD17B10 | |
| SCHEMBL23665159 | 0.83 | OPRK1 (0.42) | OPRK1PIK3CDHSD11B1SMN1; SMN2HSD17B10 | |
| SCHEMBL21870602 | 0.83 | OPRK1 (0.42) | OPRK1EPHX2EPHX1HSD11B1SMN1; SMN2 | |
| SCHEMBL13798632 | 0.82 | EPHX2 (0.46) | EPHX2EPHX1LTA4HOPRL1MAPT | |
| SCHEMBL8138855 | 0.82 | EPHX2 (0.46) | EPHX2EPHX1LTA4HOPRL1MAPT | |
| SCHEMBL12750502 | 0.82 | EPHX2 (0.46) | EPHX2EPHX1LTA4HOPRL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
| WO-2019160882-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.